Updated Results and Biomarker Analyses from the Phase 2 Trial (BBCAPX Study) of Sintilimab Plus Bevacizumab and CapeOx As First-Line Treatment in Patients with RAS-mutant, Microsatellite Stable, Unresectable Metastatic Colorectal Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Metastatic Colorectal Cancer,Bevacizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined